
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Check Cap Ltd (CHEK)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CHEK (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $7
1 Year Target Price $7
0 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.2% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.80M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.21 | 52 Weeks Range 0.56 - 3.04 | Updated Date 08/29/2025 |
52 Weeks Range 0.56 - 3.04 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Earnings Date
Report Date 2025-08-28 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.21% | Return on Equity (TTM) -53.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -20990855 | Price to Sales(TTM) - |
Enterprise Value -20990855 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.74 | Shares Outstanding 5851040 | Shares Floating 4745020 |
Shares Outstanding 5851040 | Shares Floating 4745020 | ||
Percent Insiders 18.91 | Percent Institutions 2.08 |
Upturn AI SWOT
Check Cap Ltd

Company Overview
History and Background
Check Cap Ltd is an Israeli-based company founded in 2005. It is focused on developing and commercializing C-Scan, an ingestible capsule for colon cancer screening.
Core Business Areas
- C-Scan Development: Development and enhancement of the C-Scan system for colon cancer screening.
- Commercialization: Efforts to market and sell the C-Scan system globally, primarily in areas where colon cancer screening is low.
- Clinical Trials: Conducting clinical trials to validate the safety and efficacy of C-Scan.
Leadership and Structure
Check Cap Ltd. typically has a CEO, CFO, and a board of directors. The organizational structure is likely functional, with departments for R&D, marketing, and operations.
Top Products and Market Share
Key Offerings
- C-Scan System: The C-Scan system is Check Cap's primary offering. It consists of an ingestible capsule, recording device, and analysis software used for colon cancer screening. Market share is low due to the product being in development phase but potential total addressable market is the population that requires colon cancer screening. Main competitors are colonoscopies and fecal occult blood tests (FOBT).
Market Dynamics
Industry Overview
The colon cancer screening market is large and growing, driven by an aging population and increasing awareness of early detection. Traditional screening methods include colonoscopies and stool-based tests.
Positioning
Check Cap aims to disrupt the colon cancer screening market with its non-invasive, patient-friendly C-Scan technology. It competes with existing screening methods like colonoscopies and FOBT.
Total Addressable Market (TAM)
The TAM for colon cancer screening is estimated to be in the billions of dollars globally. Check Cap's positioning focuses on individuals unwilling or unable to undergo traditional colonoscopies.
Upturn SWOT Analysis
Strengths
- Non-invasive screening method
- Patient-friendly alternative to colonoscopies
- Proprietary technology
Weaknesses
- Limited clinical data
- Regulatory hurdles for approval
- Commercialization challenges
- High cash burn rate and continued losses.
Opportunities
- Partnerships with healthcare providers
- Expansion into new markets
- Development of additional applications for the C-Scan technology
- Increased awareness of colon cancer screening importance
Threats
- Competition from established screening methods
- Reimbursement challenges from insurance companies
- Technological advancements by competitors
- Regulatory changes and delays
Competitors and Market Share
Key Competitors
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Freenome (Private)
Competitive Landscape
Check Cap's C-Scan offers a non-invasive alternative, however, competitors such as Exact Sciences hold the majority market share with their stool-based screening tests.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, primarily focused on R&D and clinical trial progress.
Future Projections: Future growth is contingent on successful commercialization of C-Scan and achieving regulatory approvals.
Recent Initiatives: Recent initiatives typically include conducting clinical trials, seeking regulatory approvals, and establishing partnerships with healthcare providers.
Summary
Check Cap Ltd is a development-stage company focused on colon cancer screening. Its innovative C-Scan technology aims to offer a non-invasive alternative to traditional methods. However, it faces significant challenges in clinical validation, regulatory approval, and commercialization, and competes against established players. The company's success depends on its ability to successfully commercialize C-Scan and capture market share. The company needs to focus on building a strong network with healthcare providers.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports (where available)
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may not be completely up-to-date. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Check Cap Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-02-19 | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees - | Website https://www.check-cap.com |
Full time employees - | Website https://www.check-cap.com |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.